8-K 1 form_8k.htm FORM_8K Form 8k












Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (date of earliest event reported): January 12, 2021




(Exact Name of Registrant as Specified in its Charter)





(State or Other Jurisdiction

of Incorporation)


File Number)

(IRS Employer

Identification Number)




17571 Von Karman Ave.

Irvine, California 92614

(Address of Principal Executive Offices

Including Zip Code)




(Registrant’s Telephone Number,

Including Area Code)


Not applicable


(Former Name or Former Address if Changed

Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

         o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


         o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



         o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


         o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.08


NASDAQ Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company      ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨



Item 7.01 Regulation FD Disclosures.


On January 12, 2021, Biomerica, Inc. (“Biomerica”) issued a press release announcing the Company has received the CE Mark for its new COVID-19 Rapid Antigen Test for detection of COVID-19 infection. The Company also announced it has already received its first European orders and plans to ship the first part of these orders in the coming weeks.

A copy of Biomerica’s press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.

The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.


Item 8.01  Other Events.


On January 8, 2021, the Company received the CE mark for its COVID-19 Rapid Antigen Test for detection of COVID-19 infection.


Item 9.01        Financial Statements and Exhibits


(d)       Exhibits.










Press Release issued January 12, 2021.




     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Biomerica, Inc.





Dated:  January 14, 2021



/s/ Zackary S. Irani




Zackary S. Irani
Chief Executive Officer